Evidence map›Paper›PMID 29725606›Full record

ReviewJournal of immunology research2018

Immunotherapies: Exploiting the Immune System for Cancer Treatment.

Jeffrey Koury, Mariana Lucero, Caleb Cato, Lawrence Chang, Joseph Geiger, Denise Henry, Jennifer Hernandez, Fion Hung, Preet Kaur, Garrett Teskey and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of immunology research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jeffrey KouryGraduate College of Biomedical Sciences, Western University of Health Sciences, Pomona, CA 91766, USA.ORCID 0000-0002-7368-4891
Mariana LuceroGraduate College of Biomedical Sciences, Western University of Health Sciences, Pomona, CA 91766, USA.ORCID 0000-0002-9173-4768
Caleb CatoGraduate College of Biomedical Sciences, Western University of Health Sciences, Pomona, CA 91766, USA.
Lawrence ChangGraduate College of Biomedical Sciences, Western University of Health Sciences, Pomona, CA 91766, USA.ORCID 0000-0002-2938-5309
Joseph GeigerGraduate College of Biomedical Sciences, Western University of Health Sciences, Pomona, CA 91766, USA.
Denise HenryGraduate College of Biomedical Sciences, Western University of Health Sciences, Pomona, CA 91766, USA.
Jennifer HernandezGraduate College of Biomedical Sciences, Western University of Health Sciences, Pomona, CA 91766, USA.
Fion HungGraduate College of Biomedical Sciences, Western University of Health Sciences, Pomona, CA 91766, USA.ORCID 0000-0003-0829-2223
Preet KaurGraduate College of Biomedical Sciences, Western University of Health Sciences, Pomona, CA 91766, USA.
Garrett TeskeyGraduate College of Biomedical Sciences, Western University of Health Sciences, Pomona, CA 91766, USA.
Andrew TranGraduate College of Biomedical Sciences, Western University of Health Sciences, Pomona, CA 91766, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is a condition that has plagued humanity for thousands of years, with the first depictions dating back to ancient Egyptian times. However, not until recent decades have biological therapeutics been developed and refined enough to safely and effectively combat cancer. Three unique immunotherapies have gained traction in recent decades: adoptive T cell transfer, checkpoint inhibitors, and bivalent antibodies. Each has led to clinically approved therapies, as well as to therapies in preclinical and ongoing clinical trials. In this review, we outline the method by which these 3 immunotherapies function as well as any major immunotherapeutic drugs developed for treating a variety of cancers.

Indexed as

AnimalsAntibodies, MonoclonalClinical Trials as TopicCostimulatory and Inhibitory T-Cell ReceptorsHumansImmunotherapyNeoplasmsT-LymphocytesAntibodies, MonoclonalCostimulatory and Inhibitory T-Cell Receptors

Identifiers

PMID29725606
PMCPMC5872614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.